全体要約
原発性硬化性胆管炎（PSC）市場は、2022年の売上高を基に、2023年から2029年にかけての地域別および市場セクター別の予測を提供します。アメリカ、ヨーロッパ、中国などの主要地域での市場成長が見込まれ、特に医療治療や肝移植が重要なセグメントとなります。主要企業には、Acorda Therapeutics、Gilead Sciences、Intercept Pharmaceuticalsなどが含まれ、2022年には上位2社が市場の大部分を占めました。
このレポートは、原発性硬化性胆管炎（PSC）の市場動向、ドライバー、影響要因を評価し、製品タイプやアプリケーション、地域別に分けて成長機会を強調します。市場は、病院やクリニックなどのアプリケーションに基づいてセグメント化され、今後の成長が期待されています。
関連する質問
Acorda Therapeutics, Gilead Sciences, NGM Biopharmaceuticals, Intercept Pharmaceuticals, Dr. Falk Pharma, Allergan, Shire, Durect Corporation, Conatus Pharmaceuticals, Sirnaomics, Shenzhen HighTide Biopharmaceutical, Glenmark, Impax Laboratories, Mylan, Teva Pharmaceuticals, Daewoong Pharmaceutical, Mitsubishi Tanabe Pharma, Lannett
市場セグメンテーションによる詳細な分析, 主要企業の戦略と市場ポジション, 地域別の成長機会
概要
このインサイトレポートは、世界の一次硬化性胆管炎（PSC）環境に関する包括的な分析を提供し、製品セグメンテーション、企業形成、収益、市場シェア、最新の開発、M&A活動に関連する主要なトレンドを強調しています。このレポートはまた、一次硬化性胆管炎（PSC）ポートフォリオや能力、市場参入戦略、市場ポジション、地理的フットプリントに焦点を当てた、主要なグローバル企業の戦略を分析し、加速する世界の一次硬化性胆管炎（PSC）市場におけるこれらの企業の独自の立ち位置をよりよく理解します。
このインサイトレポートは、原発性硬化性胆管炎（PSC）に関する世界的な展望を形作る主要な市場動向、ドライバー、および影響要因を評価し、タイプ、用途、地理、そして市場規模別に予測を分解して、新たな機会のポケットを強調しています。数百のボトムアップの定性的および定量的な市場データに基づいた透明性のある方法論を用いたこの調査予測は、グローバルな原発性硬化性胆管炎（PSC）の現在の状態と将来の軌道に対する非常に詳細な見解を提供します。
世界の原発性硬化性胆管炎（PSC）市場の規模は、2022年のXX米ドルから2029年のXX米ドルに成長すると予測されています。2023年から2029年までの期間でCAGR%の成長が期待されています。
アメリカ合衆国の原発性硬化性胆管炎（PSC）市場は、2022年のXX米ドルから2029年にはXX米ドルに増加すると予想されており、2023年から2029年の間にXX%の CAGRを記録する見込みです。
中国の原発性硬化性胆管炎（PSC）市場は、2022年にXX米ドルから2029年までにXX米ドルに増加することが見込まれており、2023年から2029年の間にXX%の年平均成長率（CAGR）が予測されています。
ヨーロッパの一次硬化性胆管炎（PSC）市場は、2022年のXX米ドルから2029年までにXX米ドルに増加する見込みで、2023年から2029年の間にCAGRはXX%です。
主要なグローバルプライマリ硬化性胆管炎（PSC）プレーヤーには、Acorda Therapeutics、Gilead Sciences、NGM Biopharmaceuticals、Intercept Pharmaceuticals、Dr. Falk Pharma、Allergan、Shire、Durect Corporation、Conatus Pharmaceuticalsなどが含まれます。収益の面では、2022年において、世界の2社がほぼXX%のシェアを占めていました。
この報告書は、製品タイプ、アプリケーション、主要プレーヤー、および主要地域と国による原発性硬化性胆管炎（PSC）市場の包括的な概要、市場シェア、成長機会を提供します。
市場セグメンテーション：
タイプ別セグメンテーション
医療治療
肝移植
その他
アプリケーション別のセグメンテーション
病院
クリニック
その他
この報告書では、地域別に市場を分割しています：
アメリカ大陸
アメリカ合衆国
カナダ
メキシコ
ブラジル
アジア太平洋地域
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
中東およびアフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
下記のプロファイルに掲載されている企業は、主要な専門家から集めた情報や、その企業のカバレッジ、製品ポートフォリオ、市場浸透率を分析した結果に基づいて選定されています。
アコーダ・セラピューティクス
ギリアド・サイエンシズ
NGMバイオファーマシューティカルズ
インタセプトファーマシューティカルズ
ファルクファーマ博士
アラガン
シャイア
デュレクト社
コナタス・ファーマシューティカルズ
サイラノミクス
深セン・ハイタイド・バイオファーマシューティカル
グレンマーク
インパックス・ラボラトリーズ
マイラン
テバ製薬
大熊製薬
三菱田辺製薬
ランネット
※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。
目次
1 調査範囲
1.1 市場イントロダクション
1.2 対象年
1.3 調査目的
1.4 市場調査手法
1.5 調査プロセスとデータソース
1.6 経済指標
1.7 通貨
1.8 市場予測における留意事項
2 エグゼクティブサマリー
2.1 世界市場概要
2.1.1 グローバルの原発性硬化性胆管炎 （PSC）市場規模、（2018年～2029年）
2.1.2 原発性硬化性胆管炎 （PSC）市場規模、CAGR（地域別）（2018年 vs 2022年 vs 2029年）
2.2 原発性硬化性胆管炎 （PSC）セグメント、タイプ別
2.2.1 治療
2.2.2 肝移植
2.2.3 その他
2.3 原発性硬化性胆管炎 （PSC）市場規模：タイプ別
2.3.1 原発性硬化性胆管炎 （PSC）市場規模、CAGR（タイプ別）（2018年 vs 2022年 vs 2029年）
2.3.2 グローバルの原発性硬化性胆管炎 （PSC）市場規模、市場シェア（タイプ別）（2018年～2023年）
2.4 原発性硬化性胆管炎 （PSC）セグメント、用途別
2.4.1 病院
2.4.2 クリニック
2.4.3 その他
2.5 原発性硬化性胆管炎 （PSC）市場規模：用途別
2.5.1 原発性硬化性胆管炎 （PSC）市場規模、CAGR（用途別）（2018年 vs 2022年 vs 2029年）
2.5.2 グローバルの原発性硬化性胆管炎 （PSC）市場規模、市場シェア（用途別）（2018年～2023年）
3 原発性硬化性胆管炎 （PSC）市場規模：プレイヤー別
3.1 原発性硬化性胆管炎 （PSC）市場規模、市場シェア（プレイヤー別）
3.1.1 グローバルにおける原発性硬化性胆管炎 （PSC）市場の収益規模、プレイヤー別（2018年～2023年）
3.1.2 グローバルにおける原発性硬化性胆管炎 （PSC）市場の収益シェア、プレイヤー別（2018年～2023年）
3.2 グローバルの原発性硬化性胆管炎 （PSC）市場キープレイヤー拠点および提供製品
3.3 市場集中度分析
3.3.1 競合情勢分析
3.3.2 集中度レシオ（CR3、CR5、CR10）（2021年～2023年）
3.4 新製品・潜在的参入
3.5 M&A、拡大
4 原発性硬化性胆管炎 （PSC）、地域別
4.1 原発性硬化性胆管炎 （PSC）市場規模（地域別）（2018年～2023年）
4.2 アメリカズにおける原発性硬化性胆管炎 （PSC）市場規模成長（2018年〜2023年）
4.3 APACにおける原発性硬化性胆管炎 （PSC）市場規模成長（2018年〜2023年）
4.4 ヨーロッパにおける原発性硬化性胆管炎 （PSC）市場規模成長（2018年〜2023年）
4.5 中東・アフリカにおける原発性硬化性胆管炎 （PSC）市場規模成長（2018年〜2023年）
5 アメリカズ
5.1 アメリカズにおける原発性硬化性胆管炎 （PSC）市場規模、国別（2018年〜2023年）
5.2 アメリカズにおける原発性硬化性胆管炎 （PSC）市場規模、タイプ別（2018年〜2023年）
5.3 アメリカズにおける原発性硬化性胆管炎 （PSC）市場規模、用途別（2018年〜2023年）
5.4 米国
5.5 カナダ
5.6 メキシコ
5.7 ブラジル
6 APAC
6.1 APACにおける原発性硬化性胆管炎 （PSC）市場規模、地域別（2018年〜2023年）
6.2 APACにおける原発性硬化性胆管炎 （PSC）市場規模、タイプ別（2018年〜2023年）
6.3 APACにおける原発性硬化性胆管炎 （PSC）市場規模、用途別（2018年〜2023年）
6.4 中国
6.5 日本
6.6 韓国
6.7 東南アジア
6.8 インド
6.9 オーストラリア
7 ヨーロッパ
7.1 ヨーロッパの原発性硬化性胆管炎 （PSC） 国別（2018年～2023年）
7.2 ヨーロッパにおける原発性硬化性胆管炎 （PSC）市場規模、タイプ別（2018年〜2023年）
7.3 ヨーロッパにおける原発性硬化性胆管炎 （PSC）市場規模、用途別（2018年〜2023年）
7.4 ドイツ
7.5 フランス
7.6 英国
7.7 イタリア
7.8 ロシア
8 中東・アフリカ
8.1 中東・アフリカの原発性硬化性胆管炎 （PSC） 地域別（2018年～2023年）
8.2 中東・アフリカにおける原発性硬化性胆管炎 （PSC）市場規模、タイプ別（2018年〜2023年）
8.3 中東・アフリカにおける原発性硬化性胆管炎 （PSC）市場規模、用途別（2018年〜2023年）
8.4 エジプト
8.5 南アフリカ
8.6 イスラエル
8.7 トルコ
8.8 GCC地域
9 市場ドライバー・課題・トレンド
9.1 市場ドライバー・成長機会
9.2 市場課題・リスク
9.3 業界トレンド
10 グローバルの原発性硬化性胆管炎 （PSC）市場、市場予測
10.1 グローバルの原発性硬化性胆管炎 （PSC）、市場予測（地域別）（2024年～2029年）
10.1.1 グローバルの原発性硬化性胆管炎 （PSC）、市場予測（地域別）（2024年～2029年）
10.1.2 アメリカズの原発性硬化性胆管炎 （PSC）、市場予測
10.1.3 APACの原発性硬化性胆管炎 （PSC）、市場予測
10.1.4 ヨーロッパの原発性硬化性胆管炎 （PSC）、市場予測
10.1.5 中東・アフリカの原発性硬化性胆管炎 （PSC）、市場予測
10.2 アメリカズの原発性硬化性胆管炎 （PSC）、市場予測（国別）（2024年～2029年）
10.3 APACの原発性硬化性胆管炎 （PSC）、市場予測（地域別）（2024年～2029年）
10.4 ヨーロッパの原発性硬化性胆管炎 （PSC）、市場予測（国別）（2024年～2029年）
10.5 中東・アフリカの原発性硬化性胆管炎 （PSC）、市場予測（地域別）（2024年～2029年）
10.6 グローバルの原発性硬化性胆管炎 （PSC）、市場予測（タイプ別）（2024年～2029年）
10.7 グローバルの原発性硬化性胆管炎 （PSC）、市場予測（用途別）（2024年～2029年）
11 キープレイヤー分析
11.1 Acorda Therapeutics
11.1.1 Acorda Therapeutics：企業情報
11.1.2 Acorda Therapeutics：原発性硬化性胆管炎 （PSC）分野の提供製品
11.1.3 Acorda Therapeutics：原発性硬化性胆管炎 （PSC）収益・グロスマージンおよび市場シェア（2018年～2023年）
11.1.4 Acorda Therapeutics：主要事業概要
11.1.5 Acorda Therapeutics：直近の展開
11.2 Gilead Sciences
11.2.1 Gilead Sciences：企業情報
11.2.2 Gilead Sciences：原発性硬化性胆管炎 （PSC）分野の提供製品
11.2.3 Gilead Sciences：原発性硬化性胆管炎 （PSC）収益・グロスマージンおよび市場シェア（2018年～2023年）
11.2.4 Gilead Sciences：主要事業概要
11.2.5 Gilead Sciences：直近の展開
11.3 NGM Biopharmaceuticals
11.3.1 NGM Biopharmaceuticals：企業情報
11.3.2 NGM Biopharmaceuticals：原発性硬化性胆管炎 （PSC）分野の提供製品
11.3.3 NGM Biopharmaceuticals：原発性硬化性胆管炎 （PSC）収益・グロスマージンおよび市場シェア（2018年～2023年）
11.3.4 NGM Biopharmaceuticals：主要事業概要
11.3.5 NGM Biopharmaceuticals：直近の展開
11.4 Intercept Pharmaceuticals
11.4.1 Intercept Pharmaceuticals：企業情報
11.4.2 Intercept Pharmaceuticals：原発性硬化性胆管炎 （PSC）分野の提供製品
11.4.3 Intercept Pharmaceuticals：原発性硬化性胆管炎 （PSC）収益・グロスマージンおよび市場シェア（2018年～2023年）
11.4.4 Intercept Pharmaceuticals：主要事業概要
11.4.5 Intercept Pharmaceuticals：直近の展開
11.5 Dr\. Falk Pharma
11.5.1 Dr\. Falk Pharma：企業情報
11.5.2 Dr\. Falk Pharma：原発性硬化性胆管炎 （PSC）分野の提供製品
11.5.3 Dr\. Falk Pharma：原発性硬化性胆管炎 （PSC）収益・グロスマージンおよび市場シェア（2018年～2023年）
11.5.4 Dr\. Falk Pharma：主要事業概要
11.5.5 Dr\. Falk Pharma：直近の展開
11.6 Allergan
11.6.1 Allergan：企業情報
11.6.2 Allergan：原発性硬化性胆管炎 （PSC）分野の提供製品
11.6.3 Allergan：原発性硬化性胆管炎 （PSC）収益・グロスマージンおよび市場シェア（2018年～2023年）
11.6.4 Allergan：主要事業概要
11.6.5 Allergan：直近の展開
11.7 Shire
11.7.1 Shire：企業情報
11.7.2 Shire：原発性硬化性胆管炎 （PSC）分野の提供製品
11.7.3 Shire：原発性硬化性胆管炎 （PSC）収益・グロスマージンおよび市場シェア（2018年～2023年）
11.7.4 Shire：主要事業概要
11.7.5 Shire：直近の展開
11.8 Durect Corporation
11.8.1 Durect Corporation：企業情報
11.8.2 Durect Corporation：原発性硬化性胆管炎 （PSC）分野の提供製品
11.8.3 Durect Corporation：原発性硬化性胆管炎 （PSC）収益・グロスマージンおよび市場シェア（2018年～2023年）
11.8.4 Durect Corporation：主要事業概要
11.8.5 Durect Corporation：直近の展開
11.9 Conatus Pharmaceuticals
11.9.1 Conatus Pharmaceuticals：企業情報
11.9.2 Conatus Pharmaceuticals：原発性硬化性胆管炎 （PSC）分野の提供製品
11.9.3 Conatus Pharmaceuticals：原発性硬化性胆管炎 （PSC）収益・グロスマージンおよび市場シェア（2018年～2023年）
11.9.4 Conatus Pharmaceuticals：主要事業概要
11.9.5 Conatus Pharmaceuticals：直近の展開
11.10 Sirnaomics
11.10.1 Sirnaomics：企業情報
11.10.2 Sirnaomics：原発性硬化性胆管炎 （PSC）分野の提供製品
11.10.3 Sirnaomics：原発性硬化性胆管炎 （PSC）収益・グロスマージンおよび市場シェア（2018年～2023年）
11.10.4 Sirnaomics：主要事業概要
11.10.5 Sirnaomics：直近の展開
11.11 Shenzhen HighTide Biopharmaceutical
11.11.1 Shenzhen HighTide Biopharmaceutical：企業情報
11.11.2 Shenzhen HighTide Biopharmaceutical：原発性硬化性胆管炎 （PSC）分野の提供製品
11.11.3 Shenzhen HighTide Biopharmaceutical：原発性硬化性胆管炎 （PSC）収益・グロスマージンおよび市場シェア（2018年～2023年）
11.11.4 Shenzhen HighTide Biopharmaceutical：主要事業概要
11.11.5 Shenzhen HighTide Biopharmaceutical：直近の展開
11.12 Glenmark
11.12.1 Glenmark：企業情報
11.12.2 Glenmark：原発性硬化性胆管炎 （PSC）分野の提供製品
11.12.3 Glenmark：原発性硬化性胆管炎 （PSC）収益・グロスマージンおよび市場シェア（2018年～2023年）
11.12.4 Glenmark：主要事業概要
11.12.5 Glenmark：直近の展開
11.13 Impax Laboratories
11.13.1 Impax Laboratories：企業情報
11.13.2 Impax Laboratories：原発性硬化性胆管炎 （PSC）分野の提供製品
11.13.3 Impax Laboratories：原発性硬化性胆管炎 （PSC）収益・グロスマージンおよび市場シェア（2018年～2023年）
11.13.4 Impax Laboratories：主要事業概要
11.13.5 Impax Laboratories：直近の展開
11.14 Mylan
11.14.1 Mylan：企業情報
11.14.2 Mylan：原発性硬化性胆管炎 （PSC）分野の提供製品
11.14.3 Mylan：原発性硬化性胆管炎 （PSC）収益・グロスマージンおよび市場シェア（2018年～2023年）
11.14.4 Mylan：主要事業概要
11.14.5 Mylan：直近の展開
11.15 Teva Pharmaceuticals
11.15.1 Teva Pharmaceuticals：企業情報
11.15.2 Teva Pharmaceuticals：原発性硬化性胆管炎 （PSC）分野の提供製品
11.15.3 Teva Pharmaceuticals：原発性硬化性胆管炎 （PSC）収益・グロスマージンおよび市場シェア（2018年～2023年）
11.15.4 Teva Pharmaceuticals：主要事業概要
11.15.5 Teva Pharmaceuticals：直近の展開
11.16 Daewoong Pharmaceutical
11.16.1 Daewoong Pharmaceutical：企業情報
11.16.2 Daewoong Pharmaceutical：原発性硬化性胆管炎 （PSC）分野の提供製品
11.16.3 Daewoong Pharmaceutical：原発性硬化性胆管炎 （PSC）収益・グロスマージンおよび市場シェア（2018年～2023年）
11.16.4 Daewoong Pharmaceutical：主要事業概要
11.16.5 Daewoong Pharmaceutical：直近の展開
11.17 Mitsubishi Tanabe Pharma
11.17.1 Mitsubishi Tanabe Pharma：企業情報
11.17.2 Mitsubishi Tanabe Pharma：原発性硬化性胆管炎 （PSC）分野の提供製品
11.17.3 Mitsubishi Tanabe Pharma：原発性硬化性胆管炎 （PSC）収益・グロスマージンおよび市場シェア（2018年～2023年）
11.17.4 Mitsubishi Tanabe Pharma：主要事業概要
11.17.5 Mitsubishi Tanabe Pharma：直近の展開
11.18 Lannett
11.18.1 Lannett：企業情報
11.18.2 Lannett：原発性硬化性胆管炎 （PSC）分野の提供製品
11.18.3 Lannett：原発性硬化性胆管炎 （PSC）収益・グロスマージンおよび市場シェア（2018年～2023年）
11.18.4 Lannett：主要事業概要
11.18.5 Lannett：直近の展開
12 調査の結果・結論
※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”
Description
This Insight Report provides a comprehensive analysis of the global Primary Sclerosing Cholangitis (PSC) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Primary Sclerosing Cholangitis (PSC) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Primary Sclerosing Cholangitis (PSC) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Primary Sclerosing Cholangitis (PSC) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Primary Sclerosing Cholangitis (PSC).
The global Primary Sclerosing Cholangitis (PSC) market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Primary Sclerosing Cholangitis (PSC) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Primary Sclerosing Cholangitis (PSC) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Primary Sclerosing Cholangitis (PSC) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Primary Sclerosing Cholangitis (PSC) players cover Acorda Therapeutics, Gilead Sciences, NGM Biopharmaceuticals, Intercept Pharmaceuticals, Dr. Falk Pharma, Allergan, Shire, Durect Corporation and Conatus Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Primary Sclerosing Cholangitis (PSC) market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Medical Treatement
Liver Transplantation
Others
Segmentation by application
Hospital
Clinics
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Acorda Therapeutics
Gilead Sciences
NGM Biopharmaceuticals
Intercept Pharmaceuticals
Dr. Falk Pharma
Allergan
Shire
Durect Corporation
Conatus Pharmaceuticals
Sirnaomics
Shenzhen HighTide Biopharmaceutical
Glenmark
Impax Laboratories
Mylan
Teva Pharmaceuticals
Daewoong Pharmaceutical
Mitsubishi Tanabe Pharma
Lannett
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Primary Sclerosing Cholangitis (PSC) Market Size 2018-2029
2.1.2 Primary Sclerosing Cholangitis (PSC) Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Primary Sclerosing Cholangitis (PSC) Segment by Type
2.2.1 Medical Treatement
2.2.2 Liver Transplantation
2.2.3 Others
2.3 Primary Sclerosing Cholangitis (PSC) Market Size by Type
2.3.1 Primary Sclerosing Cholangitis (PSC) Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2018-2023)
2.4 Primary Sclerosing Cholangitis (PSC) Segment by Application
2.4.1 Hospital
2.4.2 Clinics
2.4.3 Others
2.5 Primary Sclerosing Cholangitis (PSC) Market Size by Application
2.5.1 Primary Sclerosing Cholangitis (PSC) Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2018-2023)
3 Primary Sclerosing Cholangitis (PSC) Market Size by Player
3.1 Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Players
3.1.1 Global Primary Sclerosing Cholangitis (PSC) Revenue by Players (2018-2023)
3.1.2 Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Players (2018-2023)
3.2 Global Primary Sclerosing Cholangitis (PSC) Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Primary Sclerosing Cholangitis (PSC) by Regions
4.1 Primary Sclerosing Cholangitis (PSC) Market Size by Regions (2018-2023)
4.2 Americas Primary Sclerosing Cholangitis (PSC) Market Size Growth (2018-2023)
4.3 APAC Primary Sclerosing Cholangitis (PSC) Market Size Growth (2018-2023)
4.4 Europe Primary Sclerosing Cholangitis (PSC) Market Size Growth (2018-2023)
4.5 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size Growth (2018-2023)
5 Americas
5.1 Americas Primary Sclerosing Cholangitis (PSC) Market Size by Country (2018-2023)
5.2 Americas Primary Sclerosing Cholangitis (PSC) Market Size by Type (2018-2023)
5.3 Americas Primary Sclerosing Cholangitis (PSC) Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Primary Sclerosing Cholangitis (PSC) Market Size by Region (2018-2023)
6.2 APAC Primary Sclerosing Cholangitis (PSC) Market Size by Type (2018-2023)
6.3 APAC Primary Sclerosing Cholangitis (PSC) Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Primary Sclerosing Cholangitis (PSC) by Country (2018-2023)
7.2 Europe Primary Sclerosing Cholangitis (PSC) Market Size by Type (2018-2023)
7.3 Europe Primary Sclerosing Cholangitis (PSC) Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Primary Sclerosing Cholangitis (PSC) by Region (2018-2023)
8.2 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Type (2018-2023)
8.3 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Primary Sclerosing Cholangitis (PSC) Market Forecast
10.1 Global Primary Sclerosing Cholangitis (PSC) Forecast by Regions (2024-2029)
10.1.1 Global Primary Sclerosing Cholangitis (PSC) Forecast by Regions (2024-2029)
10.1.2 Americas Primary Sclerosing Cholangitis (PSC) Forecast
10.1.3 APAC Primary Sclerosing Cholangitis (PSC) Forecast
10.1.4 Europe Primary Sclerosing Cholangitis (PSC) Forecast
10.1.5 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Forecast
10.2 Americas Primary Sclerosing Cholangitis (PSC) Forecast by Country (2024-2029)
10.2.1 United States Primary Sclerosing Cholangitis (PSC) Market Forecast
10.2.2 Canada Primary Sclerosing Cholangitis (PSC) Market Forecast
10.2.3 Mexico Primary Sclerosing Cholangitis (PSC) Market Forecast
10.2.4 Brazil Primary Sclerosing Cholangitis (PSC) Market Forecast
10.3 APAC Primary Sclerosing Cholangitis (PSC) Forecast by Region (2024-2029)
10.3.1 China Primary Sclerosing Cholangitis (PSC) Market Forecast
10.3.2 Japan Primary Sclerosing Cholangitis (PSC) Market Forecast
10.3.3 Korea Primary Sclerosing Cholangitis (PSC) Market Forecast
10.3.4 Southeast Asia Primary Sclerosing Cholangitis (PSC) Market Forecast
10.3.5 India Primary Sclerosing Cholangitis (PSC) Market Forecast
10.3.6 Australia Primary Sclerosing Cholangitis (PSC) Market Forecast
10.4 Europe Primary Sclerosing Cholangitis (PSC) Forecast by Country (2024-2029)
10.4.1 Germany Primary Sclerosing Cholangitis (PSC) Market Forecast
10.4.2 France Primary Sclerosing Cholangitis (PSC) Market Forecast
10.4.3 UK Primary Sclerosing Cholangitis (PSC) Market Forecast
10.4.4 Italy Primary Sclerosing Cholangitis (PSC) Market Forecast
10.4.5 Russia Primary Sclerosing Cholangitis (PSC) Market Forecast
10.5 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Forecast by Region (2024-2029)
10.5.1 Egypt Primary Sclerosing Cholangitis (PSC) Market Forecast
10.5.2 South Africa Primary Sclerosing Cholangitis (PSC) Market Forecast
10.5.3 Israel Primary Sclerosing Cholangitis (PSC) Market Forecast
10.5.4 Turkey Primary Sclerosing Cholangitis (PSC) Market Forecast
10.5.5 GCC Countries Primary Sclerosing Cholangitis (PSC) Market Forecast
10.6 Global Primary Sclerosing Cholangitis (PSC) Forecast by Type (2024-2029)
10.7 Global Primary Sclerosing Cholangitis (PSC) Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Acorda Therapeutics
11.1.1 Acorda Therapeutics Company Information
11.1.2 Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Product Offered
11.1.3 Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Acorda Therapeutics Main Business Overview
11.1.5 Acorda Therapeutics Latest Developments
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Information
11.2.2 Gilead Sciences Primary Sclerosing Cholangitis (PSC) Product Offered
11.2.3 Gilead Sciences Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Gilead Sciences Main Business Overview
11.2.5 Gilead Sciences Latest Developments
11.3 NGM Biopharmaceuticals
11.3.1 NGM Biopharmaceuticals Company Information
11.3.2 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered
11.3.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 NGM Biopharmaceuticals Main Business Overview
11.3.5 NGM Biopharmaceuticals Latest Developments
11.4 Intercept Pharmaceuticals
11.4.1 Intercept Pharmaceuticals Company Information
11.4.2 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered
11.4.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Intercept Pharmaceuticals Main Business Overview
11.4.5 Intercept Pharmaceuticals Latest Developments
11.5 Dr. Falk Pharma
11.5.1 Dr. Falk Pharma Company Information
11.5.2 Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Product Offered
11.5.3 Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Dr. Falk Pharma Main Business Overview
11.5.5 Dr. Falk Pharma Latest Developments
11.6 Allergan
11.6.1 Allergan Company Information
11.6.2 Allergan Primary Sclerosing Cholangitis (PSC) Product Offered
11.6.3 Allergan Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Allergan Main Business Overview
11.6.5 Allergan Latest Developments
11.7 Shire
11.7.1 Shire Company Information
11.7.2 Shire Primary Sclerosing Cholangitis (PSC) Product Offered
11.7.3 Shire Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Shire Main Business Overview
11.7.5 Shire Latest Developments
11.8 Durect Corporation
11.8.1 Durect Corporation Company Information
11.8.2 Durect Corporation Primary Sclerosing Cholangitis (PSC) Product Offered
11.8.3 Durect Corporation Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Durect Corporation Main Business Overview
11.8.5 Durect Corporation Latest Developments
11.9 Conatus Pharmaceuticals
11.9.1 Conatus Pharmaceuticals Company Information
11.9.2 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered
11.9.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Conatus Pharmaceuticals Main Business Overview
11.9.5 Conatus Pharmaceuticals Latest Developments
11.10 Sirnaomics
11.10.1 Sirnaomics Company Information
11.10.2 Sirnaomics Primary Sclerosing Cholangitis (PSC) Product Offered
11.10.3 Sirnaomics Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Sirnaomics Main Business Overview
11.10.5 Sirnaomics Latest Developments
11.11 Shenzhen HighTide Biopharmaceutical
11.11.1 Shenzhen HighTide Biopharmaceutical Company Information
11.11.2 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Product Offered
11.11.3 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Shenzhen HighTide Biopharmaceutical Main Business Overview
11.11.5 Shenzhen HighTide Biopharmaceutical Latest Developments
11.12 Glenmark
11.12.1 Glenmark Company Information
11.12.2 Glenmark Primary Sclerosing Cholangitis (PSC) Product Offered
11.12.3 Glenmark Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Glenmark Main Business Overview
11.12.5 Glenmark Latest Developments
11.13 Impax Laboratories
11.13.1 Impax Laboratories Company Information
11.13.2 Impax Laboratories Primary Sclerosing Cholangitis (PSC) Product Offered
11.13.3 Impax Laboratories Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Impax Laboratories Main Business Overview
11.13.5 Impax Laboratories Latest Developments
11.14 Mylan
11.14.1 Mylan Company Information
11.14.2 Mylan Primary Sclerosing Cholangitis (PSC) Product Offered
11.14.3 Mylan Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Mylan Main Business Overview
11.14.5 Mylan Latest Developments
11.15 Teva Pharmaceuticals
11.15.1 Teva Pharmaceuticals Company Information
11.15.2 Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered
11.15.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Teva Pharmaceuticals Main Business Overview
11.15.5 Teva Pharmaceuticals Latest Developments
11.16 Daewoong Pharmaceutical
11.16.1 Daewoong Pharmaceutical Company Information
11.16.2 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Product Offered
11.16.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 Daewoong Pharmaceutical Main Business Overview
11.16.5 Daewoong Pharmaceutical Latest Developments
11.17 Mitsubishi Tanabe Pharma
11.17.1 Mitsubishi Tanabe Pharma Company Information
11.17.2 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Product Offered
11.17.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2018-2023)
11.17.4 Mitsubishi Tanabe Pharma Main Business Overview
11.17.5 Mitsubishi Tanabe Pharma Latest Developments
11.18 Lannett
11.18.1 Lannett Company Information
11.18.2 Lannett Primary Sclerosing Cholangitis (PSC) Product Offered
11.18.3 Lannett Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2018-2023)
11.18.4 Lannett Main Business Overview
11.18.5 Lannett Latest Developments
12 Research Findings and Conclusion
List of Tables Table 1. Primary Sclerosing Cholangitis (PSC) Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions) Table 2. Major Players of Medical Treatement Table 3. Major Players of Liver Transplantation Table 4. Major Players of Others Table 5. Primary Sclerosing Cholangitis (PSC) Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions) Table 6. Global Primary Sclerosing Cholangitis (PSC) Market Size by Type (2018-2023) & ($ Millions) Table 7. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2018-2023) Table 8. Primary Sclerosing Cholangitis (PSC) Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions) Table 9. Global Primary Sclerosing Cholangitis (PSC) Market Size by Application (2018-2023) & ($ Millions) Table 10. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2018-2023) Table 11. Global Primary Sclerosing Cholangitis (PSC) Revenue by Players (2018-2023) & ($ Millions) Table 12. Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Player (2018-2023) Table 13. Primary Sclerosing Cholangitis (PSC) Key Players Head office and Products Offered Table 14. Primary Sclerosing Cholangitis (PSC) Concentration Ratio (CR3, CR5 and CR10) & (2021-2023) Table 15. New Products and Potential Entrants Table 16. Mergers & Acquisitions, Expansion Table 17. Global Primary Sclerosing Cholangitis (PSC) Market Size by Regions 2018-2023 & ($ Millions) Table 18. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Regions (2018-2023) Table 19. Global Primary Sclerosing Cholangitis (PSC) Revenue by Country/Region (2018-2023) & ($ millions) Table 20. Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Country/Region (2018-2023) Table 21. Americas Primary Sclerosing Cholangitis (PSC) Market Size by Country (2018-2023) & ($ Millions) Table 22. Americas Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Country (2018-2023) Table 23. Americas Primary Sclerosing Cholangitis (PSC) Market Size by Type (2018-2023) & ($ Millions) Table 24. Americas Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2018-2023) Table 25. Americas Primary Sclerosing Cholangitis (PSC) Market Size by Application (2018-2023) & ($ Millions) Table 26. Americas Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2018-2023) Table 27. APAC Primary Sclerosing Cholangitis (PSC) Market Size by Region (2018-2023) & ($ Millions) Table 28. APAC Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Region (2018-2023) Table 29. APAC Primary Sclerosing Cholangitis (PSC) Market Size by Type (2018-2023) & ($ Millions) Table 30. APAC Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2018-2023) Table 31. APAC Primary Sclerosing Cholangitis (PSC) Market Size by Application (2018-2023) & ($ Millions) Table 32. APAC Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2018-2023) Table 33. Europe Primary Sclerosing Cholangitis (PSC) Market Size by Country (2018-2023) & ($ Millions) Table 34. Europe Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Country (2018-2023) Table 35. Europe Primary Sclerosing Cholangitis (PSC) Market Size by Type (2018-2023) & ($ Millions) Table 36. Europe Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2018-2023) Table 37. Europe Primary Sclerosing Cholangitis (PSC) Market Size by Application (2018-2023) & ($ Millions) Table 38. Europe Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2018-2023) Table 39. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Region (2018-2023) & ($ Millions) Table 40. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Region (2018-2023) Table 41. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Type (2018-2023) & ($ Millions) Table 42. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2018-2023) Table 43. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Application (2018-2023) & ($ Millions) Table 44. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2018-2023) Table 45. Key Market Drivers & Growth Opportunities of Primary Sclerosing Cholangitis (PSC) Table 46. Key Market Challenges & Risks of Primary Sclerosing Cholangitis (PSC) Table 47. Key Industry Trends of Primary Sclerosing Cholangitis (PSC) Table 48. Global Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Regions (2024-2029) & ($ Millions) Table 49. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share Forecast by Regions (2024-2029) Table 50. Global Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Type (2024-2029) & ($ Millions) Table 51. Global Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Application (2024-2029) & ($ Millions) Table 52. Acorda Therapeutics Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors Table 53. Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Product Offered Table 54. Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 55. Acorda Therapeutics Main Business Table 56. Acorda Therapeutics Latest Developments Table 57. Gilead Sciences Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors Table 58. Gilead Sciences Primary Sclerosing Cholangitis (PSC) Product Offered Table 59. Gilead Sciences Main Business Table 60. Gilead Sciences Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 61. Gilead Sciences Latest Developments Table 62. NGM Biopharmaceuticals Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors Table 63. NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered Table 64. NGM Biopharmaceuticals Main Business Table 65. NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 66. NGM Biopharmaceuticals Latest Developments Table 67. Intercept Pharmaceuticals Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors Table 68. Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered Table 69. Intercept Pharmaceuticals Main Business Table 70. Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 71. Intercept Pharmaceuticals Latest Developments Table 72. Dr. Falk Pharma Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors Table 73. Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Product Offered Table 74. Dr. Falk Pharma Main Business Table 75. Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 76. Dr. Falk Pharma Latest Developments Table 77. Allergan Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors Table 78. Allergan Primary Sclerosing Cholangitis (PSC) Product Offered Table 79. Allergan Main Business Table 80. Allergan Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 81. Allergan Latest Developments Table 82. Shire Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors Table 83. Shire Primary Sclerosing Cholangitis (PSC) Product Offered Table 84. Shire Main Business Table 85. Shire Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 86. Shire Latest Developments Table 87. Durect Corporation Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors Table 88. Durect Corporation Primary Sclerosing Cholangitis (PSC) Product Offered Table 89. Durect Corporation Main Business Table 90. Durect Corporation Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 91. Durect Corporation Latest Developments Table 92. Conatus Pharmaceuticals Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors Table 93. Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered Table 94. Conatus Pharmaceuticals Main Business Table 95. Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 96. Conatus Pharmaceuticals Latest Developments Table 97. Sirnaomics Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors Table 98. Sirnaomics Primary Sclerosing Cholangitis (PSC) Product Offered Table 99. Sirnaomics Main Business Table 100. Sirnaomics Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 101. Sirnaomics Latest Developments Table 102. Shenzhen HighTide Biopharmaceutical Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors Table 103. Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Product Offered Table 104. Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 105. Shenzhen HighTide Biopharmaceutical Main Business Table 106. Shenzhen HighTide Biopharmaceutical Latest Developments Table 107. Glenmark Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors Table 108. Glenmark Primary Sclerosing Cholangitis (PSC) Product Offered Table 109. Glenmark Main Business Table 110. Glenmark Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 111. Glenmark Latest Developments Table 112. Impax Laboratories Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors Table 113. Impax Laboratories Primary Sclerosing Cholangitis (PSC) Product Offered Table 114. Impax Laboratories Main Business Table 115. Impax Laboratories Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 116. Impax Laboratories Latest Developments Table 117. Mylan Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors Table 118. Mylan Primary Sclerosing Cholangitis (PSC) Product Offered Table 119. Mylan Main Business Table 120. Mylan Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 121. Mylan Latest Developments Table 122. Teva Pharmaceuticals Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors Table 123. Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered Table 124. Teva Pharmaceuticals Main Business Table 125. Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 126. Teva Pharmaceuticals Latest Developments Table 127. Daewoong Pharmaceutical Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors Table 128. Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Product Offered Table 129. Daewoong Pharmaceutical Main Business Table 130. Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 131. Daewoong Pharmaceutical Latest Developments Table 132. Mitsubishi Tanabe Pharma Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors Table 133. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Product Offered Table 134. Mitsubishi Tanabe Pharma Main Business Table 135. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 136. Mitsubishi Tanabe Pharma Latest Developments Table 137. Lannett Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors Table 138. Lannett Primary Sclerosing Cholangitis (PSC) Product Offered Table 139. Lannett Main Business Table 140. Lannett Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 141. Lannett Latest Developments List of Figures Figure 1. Primary Sclerosing Cholangitis (PSC) Report Years Considered Figure 2. Research Objectives Figure 3. Research Methodology Figure 4. Research Process and Data Source Figure 5. Global Primary Sclerosing Cholangitis (PSC) Market Size Growth Rate 2018-2029 ($ Millions) Figure 6. Primary Sclerosing Cholangitis (PSC) Sales by Geographic Region (2018, 2022 & 2029) & ($ millions) Figure 7. Primary Sclerosing Cholangitis (PSC) Sales Market Share by Country/Region (2022) Figure 8. Primary Sclerosing Cholangitis (PSC) Sales Market Share by Country/Region (2018, 2022 & 2029) Figure 9. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type in 2022 Figure 10. Primary Sclerosing Cholangitis (PSC) in Hospital Figure 11. Global Primary Sclerosing Cholangitis (PSC) Market: Hospital (2018-2023) & ($ Millions) Figure 12. Primary Sclerosing Cholangitis (PSC) in Clinics Figure 13. Global Primary Sclerosing Cholangitis (PSC) Market: Clinics (2018-2023) & ($ Millions) Figure 14. Primary Sclerosing Cholangitis (PSC) in Others Figure 15. Global Primary Sclerosing Cholangitis (PSC) Market: Others (2018-2023) & ($ Millions) Figure 16. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application in 2022 Figure 17. Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Player in 2022 Figure 18. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Regions (2018-2023) Figure 19. Americas Primary Sclerosing Cholangitis (PSC) Market Size 2018-2023 ($ Millions) Figure 20. APAC Primary Sclerosing Cholangitis (PSC) Market Size 2018-2023 ($ Millions) Figure 21. Europe Primary Sclerosing Cholangitis (PSC) Market Size 2018-2023 ($ Millions) Figure 22. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size 2018-2023 ($ Millions) Figure 23. Americas Primary Sclerosing Cholangitis (PSC) Value Market Share by Country in 2022 Figure 24. United States Primary Sclerosing Cholangitis (PSC) Market Size Growth 2018-2023 ($ Millions) Figure 25. Canada Primary Sclerosing Cholangitis (PSC) Market Size Growth 2018-2023 ($ Millions) Figure 26. Mexico Primary Sclerosing Cholangitis (PSC) Market Size Growth 2018-2023 ($ Millions) Figure 27. Brazil Primary Sclerosing Cholangitis (PSC) Market Size Growth 2018-2023 ($ Millions) Figure 28. APAC Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Region in 2022 Figure 29. APAC Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type in 2022 Figure 30. APAC Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application in 2022 Figure 31. China Primary Sclerosing Cholangitis (PSC) Market Size Growth 2018-2023 ($ Millions) Figure 32. Japan Primary Sclerosing Cholangitis (PSC) Market Size Growth 2018-2023 ($ Millions) Figure 33. Korea Primary Sclerosing Cholangitis (PSC) Market Size Growth 2018-2023 ($ Millions) Figure 34. Southeast Asia Primary Sclerosing Cholangitis (PSC) Market Size Growth 2018-2023 ($ Millions) Figure 35. India Primary Sclerosing Cholangitis (PSC) Market Size Growth 2018-2023 ($ Millions) Figure 36. Australia Primary Sclerosing Cholangitis (PSC) Market Size Growth 2018-2023 ($ Millions) Figure 37. Europe Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Country in 2022 Figure 38. Europe Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2018-2023) Figure 39. Europe Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2018-2023) Figure 40. Germany Primary Sclerosing Cholangitis (PSC) Market Size Growth 2018-2023 ($ Millions) Figure 41. France Primary Sclerosing Cholangitis (PSC) Market Size Growth 2018-2023 ($ Millions) Figure 42. UK Primary Sclerosing Cholangitis (PSC) Market Size Growth 2018-2023 ($ Millions) Figure 43. Italy Primary Sclerosing Cholangitis (PSC) Market Size Growth 2018-2023 ($ Millions) Figure 44. Russia Primary Sclerosing Cholangitis (PSC) Market Size Growth 2018-2023 ($ Millions) Figure 45. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Region (2018-2023) Figure 46. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2018-2023) Figure 47. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2018-2023) Figure 48. Egypt Primary Sclerosing Cholangitis (PSC) Market Size Growth 2018-2023 ($ Millions) Figure 49. South Africa Primary Sclerosing Cholangitis (PSC) Market Size Growth 2018-2023 ($ Millions) Figure 50. Israel Primary Sclerosing Cholangitis (PSC) Market Size Growth 2018-2023 ($ Millions) Figure 51. Turkey Primary Sclerosing Cholangitis (PSC) Market Size Growth 2018-2023 ($ Millions) Figure 52. GCC Country Primary Sclerosing Cholangitis (PSC) Market Size Growth 2018-2023 ($ Millions) Figure 53. Americas Primary Sclerosing Cholangitis (PSC) Market Size 2024-2029 ($ Millions) Figure 54. APAC Primary Sclerosing Cholangitis (PSC) Market Size 2024-2029 ($ Millions) Figure 55. Europe Primary Sclerosing Cholangitis (PSC) Market Size 2024-2029 ($ Millions) Figure 56. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size 2024-2029 ($ Millions) Figure 57. United States Primary Sclerosing Cholangitis (PSC) Market Size 2024-2029 ($ Millions) Figure 58. Canada Primary Sclerosing Cholangitis (PSC) Market Size 2024-2029 ($ Millions) Figure 59. Mexico Primary Sclerosing Cholangitis (PSC) Market Size 2024-2029 ($ Millions) Figure 60. Brazil Primary Sclerosing Cholangitis (PSC) Market Size 2024-2029 ($ Millions) Figure 61. China Primary Sclerosing Cholangitis (PSC) Market Size 2024-2029 ($ Millions) Figure 62. Japan Primary Sclerosing Cholangitis (PSC) Market Size 2024-2029 ($ Millions) Figure 63. Korea Primary Sclerosing Cholangitis (PSC) Market Size 2024-2029 ($ Millions) Figure 64. Southeast Asia Primary Sclerosing Cholangitis (PSC) Market Size 2024-2029 ($ Millions) Figure 65. India Primary Sclerosing Cholangitis (PSC) Market Size 2024-2029 ($ Millions) Figure 66. Australia Primary Sclerosing Cholangitis (PSC) Market Size 2024-2029 ($ Millions) Figure 67. Germany Primary Sclerosing Cholangitis (PSC) Market Size 2024-2029 ($ Millions) Figure 68. France Primary Sclerosing Cholangitis (PSC) Market Size 2024-2029 ($ Millions) Figure 69. UK Primary Sclerosing Cholangitis (PSC) Market Size 2024-2029 ($ Millions) Figure 70. Italy Primary Sclerosing Cholangitis (PSC) Market Size 2024-2029 ($ Millions) Figure 71. Russia Primary Sclerosing Cholangitis (PSC) Market Size 2024-2029 ($ Millions) Figure 72. Spain Primary Sclerosing Cholangitis (PSC) Market Size 2024-2029 ($ Millions) Figure 73. Egypt Primary Sclerosing Cholangitis (PSC) Market Size 2024-2029 ($ Millions) Figure 74. South Africa Primary Sclerosing Cholangitis (PSC) Market Size 2024-2029 ($ Millions) Figure 75. Israel Primary Sclerosing Cholangitis (PSC) Market Size 2024-2029 ($ Millions) Figure 76. Turkey Primary Sclerosing Cholangitis (PSC) Market Size 2024-2029 ($ Millions) Figure 77. GCC Countries Primary Sclerosing Cholangitis (PSC) Market Size 2024-2029 ($ Millions) Figure 78. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share Forecast by Type (2024-2029) Figure 79. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share Forecast by Application (2024-2029)
